title: Emerging treatments and signaling pathway inhibitors.
abstract: A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway.
authors.affiliation: Stanford University School of Medicine, Palo Alto, California, USA. tangy@stanford.edu
authors.forename: Jean Y
authors.initials: JY
authors.lastname: Tang
authors.forename: Ashfaq A
authors.initials: AA
authors.lastname: Marghoob
mesh_terms: D000634:Aminoquinolines / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001478:Basal Cell Nevus Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D001549:Benzamides / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D043224:Deoxyribonuclease (Pyrimidine Dimer) / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D000077271:Imiquimod; D010778:Photochemotherapy; D011725:Pyridines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012176:Retinoids / Q000627:therapeutic use; D055502:Secondary Prevention; D015398:Signal Transduction / Q000187:drug effects*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D014764:Viral Proteins / Q000627:therapeutic use
chemical_list: D000634:Aminoquinolines; D000813:Anilides; D000970:Antineoplastic Agents; C583051:BMS-833923; D001549:Benzamides; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines; D011799:Quinazolines; D012176:Retinoids; D014764:Viral Proteins; C470698:endonuclease V, phage T4; D043224:Deoxyribonuclease (Pyrimidine Dimer); D000077271:Imiquimod; D005472:Fluorouracil